04 June 2019
: Case report
A Case Report of Atezolizumab Induced Tumor Lysis Syndrome
Unusual clinical course, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Unexpected drug reaction, Clinical situation which can not be reproduced for ethical reasons
Faisal Fa’ak1BCDEF, Diego Vanegas1BCDEF, Kofi M. Osei1ABDEFG*DOI: 10.12659/AJCR.915351
Am J Case Rep 2019; 20:785-789
Abstract
BACKGROUND: Advanced urothelial carcinoma has been associated with poor prognosis due to high resistance to chemotherapy and radiation until immunotherapeutic agents, such as atezolizumab, emerged as an option and have shown improved survival. However, atezolizumab is associated with side effects, which were mainly autoimmune. In this case study, we report on a rare case of atezolizumab-induced tumor lysis syndrome.
CASE REPORT: A 67-year-old female with a primary diagnosis of metastatic urothelial carcinoma who presented to the emergency department with generalized weakness associated with nausea and vomiting 8 days after her first cycle of atezolizumab. Laboratory values showed hyperphosphatemia, hyperuricemia, hypocalcemia, and acute kidney injury consistent with tumor lysis syndrome.
CONCLUSIONS: In our report, we highlight tumor lysis syndrome as a potential reaction to atezolizumab; a condition that requires prophylaxis and close laboratory monitoring.
Keywords: Immunotherapy, Programmed Cell Death 1 Ligand 2 Protein, Tumor Lysis Syndrome, Antibodies, Monoclonal, Humanized, Biopsy, Needle, Carcinoma, Transitional Cell, Emergency Service, Hospital, Hospice Care, Immunohistochemistry, Monitoring, Physiologic, Tomography, X-Ray Computed
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946074
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946165
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946414
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.944665
Most Viewed Current Articles
21 Jun 2024 : Case report
89,141
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
50,239
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
25,805
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
22,697
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030